Rob Daniels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rob Daniels has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Kinan Mokbel
Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, Exeter EX1 2LU, UK
6 shared publications - Ahmed Asiri
Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom, UK
3 shared publications - Ahmed Najim
Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom, UK
3 shared publications Eric Buramba
School of Health and Life Sciences, University of Exeter, Exeter, UK
3 shared publications- Hairil Rashmizal Abdul Razak
Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom, UK
3 shared publications Kato Denis
Department of Trade Statistics, National Institute of Statistics of Rwanda, Kigali, Rwanda
3 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (10) , 200
UK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England
Background/Objectives: In this retrospective aggregate pharmacovigilance study, we described UK Yellow Card reporting relative to partial English National Health Service (NHS) general practice (GP) prescribing for six glucagon-like peptide-1 (GLP-1)-based therapies. Methods: Primary overall reaction ratios used matching complete calendar years within each medicine: 2022–2025 for five medicines and 2024–2025 for tirzepatide. UK reaction counts were divided by English NHS GP items; geographical and product-coverage differences remain. Separate medicine estimates used conditional exact Poisson intervals without pooling. Annual models allowed for overdispersion. Outcome-specific extracts with unmatched windows and the combined GP plus estimated hospital denominator were secondary analyses. Results: Under the incomplete English NHS GP denominator, primary reaction ratios per million items were tirzepatide 23,808.48, semaglutide 5720.42, liraglutide 1700.45, exenatide 370.52, dulaglutide 258.11, and lixisenatide 87.70. Overall and severity report-based ratios were available for four medicines over their eligible periods. Temporal estimates were imprecise; tirzepatide had only two complete years, and lixisenatide had three reaction entries in its complete-year series, so neither received trend inference. Conclusions: Calendar matching improves the temporal definition of the overall ratios. Omitted private prescribing, UK–England population differences, uncertain product matching and reporting behaviour still prevent interpretation as incidence or comparative safety.
- 13 October 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (10) , 200
Open AccessUK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England
Background/Objectives: In this retrospective aggregate pharmacovigilance study, we described UK Yellow Card reporting relative to partial English National Health Service (NHS) general practice (GP) prescribing for six glucagon-like peptide-1 (GLP-1)-based therapies. Methods: Primary overall reaction ratios used matching complete calendar years within each medicine: 2022–2025 for five medicines and 2024–2025 for tirzepatide. UK reaction counts were divided by English NHS GP items; geographical and product-coverage differences remain. Separate medicine estimates used conditional exact Poisson intervals without pooling. Annual models allowed for overdispersion. Outcome-specific extracts with unmatched windows and the combined GP plus estimated hospital denominator were secondary analyses. Results: Under the incomplete English NHS GP denominator, primary reaction ratios per million items were tirzepatide 23,808.48, semaglutide 5720.42, liraglutide 1700.45, exenatide 370.52, dulaglutide 258.11, and lixisenatide 87.70. Overall and severity report-based ratios were available for four medicines over their eligible periods. Temporal estimates were imprecise; tirzepatide had only two complete years, and lixisenatide had three reaction entries in its complete-year series, so neither received trend inference. Conclusions: Calendar matching improves the temporal definition of the overall ratios. Omitted private prescribing, UK–England population differences, uncertain product matching and reporting behaviour still prevent interpretation as incidence or comparative safety.
- Open Access
- 9 October 2026
- Published by MDPI AG in Preprints.org
SGLT2 Inhibitor Adverse Reaction Reporting Relative to Prescribing Volume
Background/Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors share a renal mechanism but differ in SGLT1 selectivity, off-target activity and licensed indications. We compared exposure-adjusted reporting of suspected adverse reactions for canagliflozin, dapagliflozin, empagliflozin and ertugliflozin and examined whether differences between them are consistent with molecule-specific pharmacology. Methods: UK Yellow Card reaction entries for 2021–2025 were related to English NHS general practice and estimated hospital prescribed items for the same 60 months. Rates were calculated with exact Poisson intervals, reporting rate ratios (RRRs) versus dapagliflozin with Poisson regression and Holm adjustment, and annual trends with quasi-Poisson regression; within-class disproportionality was also calculated without a prescribing denominator. Results: The analysis included 8789 reaction entries and 52.19 million items. Total reporting rates were 125.47, 188.83, 143.53 and 213.64 per million items, respectively. Ketoacidosis and ketosis reporting was higher for canagliflozin (RRR 2.45, 95% CI 2.02–2.95) and empagliflozin (1.93, 1.69–2.19), as was euglycaemic ketoacidosis reporting, and peripheral tissue injury reporting was higher for canagliflozin (2.80, 1.63–4.64). Amputation reporting was higher for canagliflozin (3.69, 1.14–10.61) but not after adjustment, and 2.68 for lower-limb terms. Within the class, the entry-level ketoacidosis reporting odds ratio for canagliflozin was 3.10 (2.53–3.80). Ketoacidosis reporting declined by 32.0% per year for dapagliflozin and by 24.4% for empagliflozin. Conclusions: Higher ketoacidosis and peripheral tissue injury reporting for canagliflozin is compatible with its lower SGLT2 selectivity, but equally with population or reporting differences, which these data cannot separate. Empagliflozin does not fit a selectivity explanation. These are reporting rates, not incidence estimates.
- 9 October 2026
- Published by MDPI AG in Preprints.org
Open AccessSGLT2 Inhibitor Adverse Reaction Reporting Relative to Prescribing Volume
Background/Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors share a renal mechanism but differ in SGLT1 selectivity, off-target activity and licensed indications. We compared exposure-adjusted reporting of suspected adverse reactions for canagliflozin, dapagliflozin, empagliflozin and ertugliflozin and examined whether differences between them are consistent with molecule-specific pharmacology. Methods: UK Yellow Card reaction entries for 2021–2025 were related to English NHS general practice and estimated hospital prescribed items for the same 60 months. Rates were calculated with exact Poisson intervals, reporting rate ratios (RRRs) versus dapagliflozin with Poisson regression and Holm adjustment, and annual trends with quasi-Poisson regression; within-class disproportionality was also calculated without a prescribing denominator. Results: The analysis included 8789 reaction entries and 52.19 million items. Total reporting rates were 125.47, 188.83, 143.53 and 213.64 per million items, respectively. Ketoacidosis and ketosis reporting was higher for canagliflozin (RRR 2.45, 95% CI 2.02–2.95) and empagliflozin (1.93, 1.69–2.19), as was euglycaemic ketoacidosis reporting, and peripheral tissue injury reporting was higher for canagliflozin (2.80, 1.63–4.64). Amputation reporting was higher for canagliflozin (3.69, 1.14–10.61) but not after adjustment, and 2.68 for lower-limb terms. Within the class, the entry-level ketoacidosis reporting odds ratio for canagliflozin was 3.10 (2.53–3.80). Ketoacidosis reporting declined by 32.0% per year for dapagliflozin and by 24.4% for empagliflozin. Conclusions: Higher ketoacidosis and peripheral tissue injury reporting for canagliflozin is compatible with its lower SGLT2 selectivity, but equally with population or reporting differences, which these data cannot separate. Empagliflozin does not fit a selectivity explanation. These are reporting rates, not incidence estimates.
- Open Access
- 18 August 2026
- Published by MDPI AG in Preprints.org
Comparative Exposure-Adjusted Adverse Reaction Reporting Rates for GLP-1-Based Therapies: An Analysis of UK MHRA Yellow Card Data and NHS Prescribing Data for England
Background/Objectives: Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide are increasingly prescribed for type 2 diabetes and obesity, but post-marketing comparisons usually rest on unadjusted report counts, which reflect prescribing volume as much as risk. We estimated exposure-adjusted adverse drug reaction (ADR) reporting rates for six GLP-1-based therapies. Methods: This retrospective observational pharmacovigilance study covered February 2021 to January 2026. Suspected ADRs reported UK-wide to the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme were divided by English National Health Service (NHS) general practice (GP) and hospital prescribing volumes, combined at medicine and time-period level; hospital quantities were converted to items using GP quantity-per-item ratios. Rates per million items were pooled in a generalised linear mixed model; temporal trends used Poisson regression with a log-exposure offset. Sensitivity analyses used GP-only and hospital-only denominators and re-fitted the temporal models on reports. Results: We analysed 140,462 UK Yellow Card ADRs against 17,005,924 English NHS prescribed items. The denominator omits private prescribing, which supplies most UK weight-management use, so these rates are differentially inflated, most for tirzepatide and semaglutide. Rates per million items varied more than 200-fold: tirzepatide 27,511.52 (95% confidence interval [CI] 27,339.39–27,684.73), semaglutide 5,905.83 (5,847.98–5,964.25), liraglutide 1,326.64 (1,268.16–1,387.82), exenatide 443.36, dulaglutide 256.42 and lixisenatide 129.68; heterogeneity was extreme (I² = 99.995%) and the ordering was unchanged under both sensitivity denominators. Rates rose for semaglutide (incidence rate ratio [IRR] 1.675, 1.657–1.693) and tirzepatide (IRR 1.139, 1.118–1.160) and fell for dulaglutide (IRR 0.810, 0.774–0.848); report-based models reproduced these trends. Conclusions: Exposure-adjusted reporting rates differ markedly across GLP-1-based therapies, the newest agents reporting most. These are reporting rates under an incomplete NHS denominator, not incidence estimates; differential exposure capture and reporting behaviour prevent interpretation as comparative medicine risk.
- 18 August 2026
- Published by MDPI AG in Preprints.org
Open AccessComparative Exposure-Adjusted Adverse Reaction Reporting Rates for GLP-1-Based Therapies: An Analysis of UK MHRA Yellow Card Data and NHS Prescribing Data for England
Background/Objectives: Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide are increasingly prescribed for type 2 diabetes and obesity, but post-marketing comparisons usually rest on unadjusted report counts, which reflect prescribing volume as much as risk. We estimated exposure-adjusted adverse drug reaction (ADR) reporting rates for six GLP-1-based therapies. Methods: This retrospective observational pharmacovigilance study covered February 2021 to January 2026. Suspected ADRs reported UK-wide to the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme were divided by English National Health Service (NHS) general practice (GP) and hospital prescribing volumes, combined at medicine and time-period level; hospital quantities were converted to items using GP quantity-per-item ratios. Rates per million items were pooled in a generalised linear mixed model; temporal trends used Poisson regression with a log-exposure offset. Sensitivity analyses used GP-only and hospital-only denominators and re-fitted the temporal models on reports. Results: We analysed 140,462 UK Yellow Card ADRs against 17,005,924 English NHS prescribed items. The denominator omits private prescribing, which supplies most UK weight-management use, so these rates are differentially inflated, most for tirzepatide and semaglutide. Rates per million items varied more than 200-fold: tirzepatide 27,511.52 (95% confidence interval [CI] 27,339.39–27,684.73), semaglutide 5,905.83 (5,847.98–5,964.25), liraglutide 1,326.64 (1,268.16–1,387.82), exenatide 443.36, dulaglutide 256.42 and lixisenatide 129.68; heterogeneity was extreme (I² = 99.995%) and the ordering was unchanged under both sensitivity denominators. Rates rose for semaglutide (incidence rate ratio [IRR] 1.675, 1.657–1.693) and tirzepatide (IRR 1.139, 1.118–1.160) and fell for dulaglutide (IRR 0.810, 0.774–0.848); report-based models reproduced these trends. Conclusions: Exposure-adjusted reporting rates differ markedly across GLP-1-based therapies, the newest agents reporting most. These are reporting rates under an incomplete NHS denominator, not incidence estimates; differential exposure capture and reporting behaviour prevent interpretation as comparative medicine risk.
- 8 March 2026
- Published by Taylor & Francis in Education for Primary Care
- Vol. 37 (3-4) , 188
Protecting the last communities of practice
- 8 March 2026
- Published by Taylor & Francis in Education for Primary Care
- Vol. 37 (3-4) , 188
Protecting the last communities of practice
- Open Access
- 5 June 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (763) , e163-e174
Evaluating genotype–treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank
Background: Pharmacogenetics has the potential to optimise drug therapy and reduce adverse drug effects (ADEs) by tailoring treatment to a patient’s genotype, particularly for chronic disorders managed in general practice. However, the adoption of pharmacogenetics in general practice remains slow. Aim: To evaluate the reproducibility of previously reported associations between genomic variants and medically important adverse drug effects (MIADEs) associated with high-risk medications in general practice. Design and setting: A retrospective study using data from the UK Biobank (UKBB), a population-based cohort of over 500 000 community-based participants. Method: High-risk medications prescribed in general practice were identified by linking serious ADEs from the Yellow Card database with English general practice prescription data. These high-risk medications were then cross-examined with genomic variants associated with MIADEs from the Pharmacogenomics Knowledgebase (PharmGKB) to select variant–drug pairs for investigation within the UKBB. Results: From 78 high-risk medications prescribed in general practice and 56 PharmGKB annotations linked to MIADE risk, SLCO1B1 rs4149056 was the only variant with guideline-based prescribing recommendations. This variant, along with others of lower evidence levels, was analysed in the UKBB. No genotype–treatment interaction was observed for SLCO1B1 rs4149056 and statin-related muscle toxicity. Similarly, no interactions were detected for the remaining variants in either secondary or exploratory analyses. Conclusion: No statistically significant genotype–treatment interactions were observed for MIADE risk associated with high-risk medications in general practice. However, the limited predictive value of the assessed variants may reflect underlying phenotypic imprecision and methodological limitations. Hence, further research is needed to validate these results.
- 5 June 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (763) , e163-e174
Open AccessEvaluating genotype–treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank
Background: Pharmacogenetics has the potential to optimise drug therapy and reduce adverse drug effects (ADEs) by tailoring treatment to a patient’s genotype, particularly for chronic disorders managed in general practice. However, the adoption of pharmacogenetics in general practice remains slow. Aim: To evaluate the reproducibility of previously reported associations between genomic variants and medically important adverse drug effects (MIADEs) associated with high-risk medications in general practice. Design and setting: A retrospective study using data from the UK Biobank (UKBB), a population-based cohort of over 500 000 community-based participants. Method: High-risk medications prescribed in general practice were identified by linking serious ADEs from the Yellow Card database with English general practice prescription data. These high-risk medications were then cross-examined with genomic variants associated with MIADEs from the Pharmacogenomics Knowledgebase (PharmGKB) to select variant–drug pairs for investigation within the UKBB. Results: From 78 high-risk medications prescribed in general practice and 56 PharmGKB annotations linked to MIADE risk, SLCO1B1 rs4149056 was the only variant with guideline-based prescribing recommendations. This variant, along with others of lower evidence levels, was analysed in the UKBB. No genotype–treatment interaction was observed for SLCO1B1 rs4149056 and statin-related muscle toxicity. Similarly, no interactions were detected for the remaining variants in either secondary or exploratory analyses. Conclusion: No statistically significant genotype–treatment interactions were observed for MIADE risk associated with high-risk medications in general practice. However, the limited predictive value of the assessed variants may reflect underlying phenotypic imprecision and methodological limitations. Hence, further research is needed to validate these results.
- Open Access
- 28 November 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (749) , 538.1-538
Health inequalities and community pharmacy closures: why we should all be worried
- 28 November 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (749) , 538.1-538
Open AccessHealth inequalities and community pharmacy closures: why we should all be worried
- Open Access
- 27 November 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (23) , 2680
Improving Antimicrobial Stewardship in Acute Sore Throat: Comparison of FeverPAIN and McIsaac Scores with Molecular Point of Care Testing Using Abbott ID NOW
Background: The diagnosis of streptococcal throat infection is an area where current practice results in significant over-diagnosis of bacterial infection, with the resulting implications for antimicrobial use and resistance. The use of molecular point of care testing (POCT) has previously been shown to alter antibiotic prescribing decisions when compared to Centor scoring. This paper explores the impact of the addition of POCT to clinical assessment using the McIsaac and FeverPAIN scoring systems. Methods: Retrospective analysis of the clinical records of 144 patients who had previously received point of care testing as part of a trial of POCT as an adjunct to usual care was undertaken. The McIsaac and FeverPAIN scores were calculated and then compared with the POCT result originally obtained. The records were also reviewed to identify further consultations within 10 days of being tested. Results: Sufficient clinical data were available to calculate the FeverPAIN and McIsaac scores in 81% of patients and outcome data were available for 96.5% of patients. For patients with a FeverPAIN score of 4 or 5, 50–67% of patients had a positive POCT result, while for patients with a McIsaac score of 4 or 5, 50–68% had a positive POCT result. Moreover, 16.7% of patients who tested negative, and 16.3% of patients who tested positive, had a further consultation within 10 days of being assessed. Conclusions: Although relatively few patients in this study had maximum scores on the FeverPAIN and McIsaac scoring, the addition of POCT was shown to alter antibiotic prescribing decisions in a significant number of patients, supporting the use of Abbott ID NOW point of care testing to reduce antibiotic prescribing. Larger studies are required to confirm these results and explore the health economic aspects and potential impacts on health inequalities.
- 27 November 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (23) , 2680
Open AccessImproving Antimicrobial Stewardship in Acute Sore Throat: Comparison of FeverPAIN and McIsaac Scores with Molecular Point of Care Testing Using Abbott ID NOW
Background: The diagnosis of streptococcal throat infection is an area where current practice results in significant over-diagnosis of bacterial infection, with the resulting implications for antimicrobial use and resistance. The use of molecular point of care testing (POCT) has previously been shown to alter antibiotic prescribing decisions when compared to Centor scoring. This paper explores the impact of the addition of POCT to clinical assessment using the McIsaac and FeverPAIN scoring systems. Methods: Retrospective analysis of the clinical records of 144 patients who had previously received point of care testing as part of a trial of POCT as an adjunct to usual care was undertaken. The McIsaac and FeverPAIN scores were calculated and then compared with the POCT result originally obtained. The records were also reviewed to identify further consultations within 10 days of being tested. Results: Sufficient clinical data were available to calculate the FeverPAIN and McIsaac scores in 81% of patients and outcome data were available for 96.5% of patients. For patients with a FeverPAIN score of 4 or 5, 50–67% of patients had a positive POCT result, while for patients with a McIsaac score of 4 or 5, 50–68% had a positive POCT result. Moreover, 16.7% of patients who tested negative, and 16.3% of patients who tested positive, had a further consultation within 10 days of being assessed. Conclusions: Although relatively few patients in this study had maximum scores on the FeverPAIN and McIsaac scoring, the addition of POCT was shown to alter antibiotic prescribing decisions in a significant number of patients, supporting the use of Abbott ID NOW point of care testing to reduce antibiotic prescribing. Larger studies are required to confirm these results and explore the health economic aspects and potential impacts on health inequalities.
- Open Access
- 7 October 2024
- Published by MDPI AG in Preprints.org
Improving Antimicrobial Stewardship in Acute Sore Throat: Comparison of FeverPAIN and McIsaac Scores with Molecular Point of Care Testing Using Abbott ID NOW
The diagnosis of streptococcal throat infection is an area where current practice results in significant over diagnosis of bacterial infection with resulting implications for antimicrobial use and resistance. The use of molecular point of care (POC) testing has been shown previously to alter antibiotic prescribing decisions when compared to Centor scoring. In this study POC testing was shown to perform significantly better than FeverPAIN and McIsaac scores in the diagnosis of streptococcal throat infection providing further support for the use of Abbott ID NOW point of care testing to reduce antibiotic prescribing.
- 7 October 2024
- Published by MDPI AG in Preprints.org
Open AccessImproving Antimicrobial Stewardship in Acute Sore Throat: Comparison of FeverPAIN and McIsaac Scores with Molecular Point of Care Testing Using Abbott ID NOW
The diagnosis of streptococcal throat infection is an area where current practice results in significant over diagnosis of bacterial infection with resulting implications for antimicrobial use and resistance. The use of molecular point of care (POC) testing has been shown previously to alter antibiotic prescribing decisions when compared to Centor scoring. In this study POC testing was shown to perform significantly better than FeverPAIN and McIsaac scores in the diagnosis of streptococcal throat infection providing further support for the use of Abbott ID NOW point of care testing to reduce antibiotic prescribing.
- Open Access
- 13 September 2024
- Published by Taylor & Francis in Medical Education Online
- Vol. 29 (1) , 2403807
Belongingness in medical students: did it change during lockdown?
Belongingness has been proposed as a potential proxy for legitimate peripheral participation in medical education. Previous studies have shown good internal and external validity for tools designed to measure this variable, with potential use measuring the effectiveness of clinical teaching environments and as a marker of student wellbeing. This study examined changes in belongingness in medical students at the University of Exeter measured in spring 2019 and the equivalent period in 2021, during which COVID-19 related restrictions were in place in the United Kingdom. This study used a validated assessment tool that was self-administered via an online survey platform in 2021. Anonymised data was collected from undergraduate medical students from all years of training and results compared with previous data collected in 2019. The belongingness assessment tool described here had validity in undergraduate medical students studying at the University of Exeter and identified statistically significant changes in belongingness (as measured with this tool) between 2019 and the period during which COVID-19 restrictions were in place. These results suggest that belongingness - in undergraduate medical students fluctuates and varies under different conditions and that there was a statistically significant change during the period of lockdown restrictions. The ability to measure this key facet of educational development has the potential to monitor teaching environments to ensure optimal learning conditions for all students. Further work is required to assess whether the impacts of lockdown restrictions are transient or persist beyond the period of teaching restrictions and to determine any association with academic outcomes.
- 13 September 2024
- Published by Taylor & Francis in Medical Education Online
- Vol. 29 (1) , 2403807
Open AccessBelongingness in medical students: did it change during lockdown?
Belongingness has been proposed as a potential proxy for legitimate peripheral participation in medical education. Previous studies have shown good internal and external validity for tools designed to measure this variable, with potential use measuring the effectiveness of clinical teaching environments and as a marker of student wellbeing. This study examined changes in belongingness in medical students at the University of Exeter measured in spring 2019 and the equivalent period in 2021, during which COVID-19 related restrictions were in place in the United Kingdom. This study used a validated assessment tool that was self-administered via an online survey platform in 2021. Anonymised data was collected from undergraduate medical students from all years of training and results compared with previous data collected in 2019. The belongingness assessment tool described here had validity in undergraduate medical students studying at the University of Exeter and identified statistically significant changes in belongingness (as measured with this tool) between 2019 and the period during which COVID-19 restrictions were in place. These results suggest that belongingness - in undergraduate medical students fluctuates and varies under different conditions and that there was a statistically significant change during the period of lockdown restrictions. The ability to measure this key facet of educational development has the potential to monitor teaching environments to ensure optimal learning conditions for all students. Further work is required to assess whether the impacts of lockdown restrictions are transient or persist beyond the period of teaching restrictions and to determine any association with academic outcomes.
- Open Access
- 26 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1104
Does the Addition of Point-of-Care Testing Alter Antibiotic Prescribing Decisions When Patients Present with Acute Sore Throat to Primary Care? A Prospective Test of Change
Accurate clinical diagnosis of patients presenting to primary care settings with acute sore throat remains challenging, often resulting in the over-prescribing of antibiotics. Using point-of-care tests (POCTs) to differentiate between respiratory infections is well-accepted, yet evidence on the application within primary care is sparse. We assessed the application of testing patients (n = 160) from three family practices with suspected Streptococcal infections using rapid molecular tests (ID NOW Strep A2, Abbott). In addition to comparing clinical evaluation and prescription rates with either usual care or testing, patients and staff completed a questionnaire about their experience of molecular POCT in primary care. The immediate availability of the result was important to patients (100%), and staff (≈90%) stated that molecular testing improved the quality of care. Interestingly, only 22.73% of patients with a Centor score > 2 tested positive for Strep A and, overall, less than 50% of Centor scores 3 and 4 tested positive for Strep A with the ID NOW testing platform. The addition of rapid molecular POCTs to clinical assessment resulted in a 55–65% reduction in immediate and deferred antibiotic prescriptions. The intervention was popular with patients and medical staff but was associated with increased cost and a longer appointment length.
- 26 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1104
Open AccessDoes the Addition of Point-of-Care Testing Alter Antibiotic Prescribing Decisions When Patients Present with Acute Sore Throat to Primary Care? A Prospective Test of Change
Accurate clinical diagnosis of patients presenting to primary care settings with acute sore throat remains challenging, often resulting in the over-prescribing of antibiotics. Using point-of-care tests (POCTs) to differentiate between respiratory infections is well-accepted, yet evidence on the application within primary care is sparse. We assessed the application of testing patients (n = 160) from three family practices with suspected Streptococcal infections using rapid molecular tests (ID NOW Strep A2, Abbott). In addition to comparing clinical evaluation and prescription rates with either usual care or testing, patients and staff completed a questionnaire about their experience of molecular POCT in primary care. The immediate availability of the result was important to patients (100%), and staff (≈90%) stated that molecular testing improved the quality of care. Interestingly, only 22.73% of patients with a Centor score > 2 tested positive for Strep A and, overall, less than 50% of Centor scores 3 and 4 tested positive for Strep A with the ID NOW testing platform. The addition of rapid molecular POCTs to clinical assessment resulted in a 55–65% reduction in immediate and deferred antibiotic prescriptions. The intervention was popular with patients and medical staff but was associated with increased cost and a longer appointment length.